Genetic screening for glucocorticid-remedible aldosteronism [GRA]: experience of three clinical centres in Poland

• Autorzy: Adler G , Widecka K. , Peczkowska M. , Dobrucki T. , Placha G. , Drozd R. , Parczewski M. , Januszewicz A. , Gaciong Z. , Ciechanowicz A.
• Języki publikacji: EN

Abstrakty

EN

Glucocorticoid-remediable aldosteronism (GRA), also known as familial hyperaldosteronism type I (FH-I, OMIM 103900), is a monogenic form of inherited hypertension caused by the presence of a chimaeric gene originating from an unequal cross-over between the CYP11B1 (11ß-hydroxylase) and CYP11B2 (aldosterone synthase) genes. The hybrid gene has the CYP11B1 sequence at the 5' end, including the promoter, and the CYP11B2 sequence at the 3' end. The aim of our study was to evaluate the prevalence of GRA in a Polish population of 129 patients with primary hyperaldosteronism (PHA) and 132 patients with essential hypertension (EH), through the use of a PCR-based test revealing the chimaeric gene. None of our PHA or EH patients was positive for the CYP11BHCYP11B2 chimaeric gene. These data suggest that GRA is unlikely to be a common cause of hypertension in Polish subjects. However, the real prevalence of GRA in Poland, both in the high-risk group of individuals with primary hyperaldosteronism and in the general population, remains to be established.

• Wydawca: -
• Czasopismo: Journal of Applied Genetics
• Rocznik: 2005
• Tom: 46
• Numer: 3
• Opis fizyczny: p.329-332,fig.,ref.

Twórcy

autor

Adler G

• Pomeranian Medical University, Powstancow Wielkopolskich 72, 70-111 Szczecin, Poland

autor

Widecka K.

autor

Peczkowska M.

autor

Dobrucki T.

autor

Placha G.

autor

Drozd R.

autor

Parczewski M.

autor

Januszewicz A.

autor

Gaciong Z.

autor

Ciechanowicz A.

Bibliografia

• Ciechanowicz A, Widecka K, Drozd R, Adler G, Cyryłowski L, Czekalski S, 2001. Lack of association between Gly460Trp polymorphism of alpha-adducin gene and salt sensitivity of blood pressure in Polish hypertensives. Kidney Blood Press Res 24: 201-206.
• Fardella CE, Mosso L, Gomez-Sanchez C, Cortes P, Soto J, Gomez L, et al. 2000. Primary hyperaldosteronism in essential hypertensives: prevalence, biochemical profile, and molecular biology. J Clin Endocrinol Metab 85: 1863-1867.
• Gates LJ, Benjamin N, Haites NE, MacConnachie AA, McLay JS, 2001. Is random screening of value in detecting glucocorticoid-remediable aldosteronism within a hypertensive population? J Hum Hypertens 15: 173-176.
• Ignatowska-Świtalska H, Chodakowska J, Januszewicz W, Fełtynowski T, Adamczyk M, Lewandowski J, 1997. Evaluation of plasma aldosterone to plasma renin activity ratio in patients with primary aldosteronism. J Hum Hypertens 11: 373-378.
• Jonsson JR, Klemm SA, Tunny TJ, Stowasser M, Gordon RD, 1995. A new genetic test for familial hyperaldosteronism type I aids in the detection of curable hypertension. Biochem Biophys Res Commun 207: 565-571.
• Lifton RP, Dluhy RG, Powers M, Rich GM, Cook S, Ulick S, Lalouel JM, 1992. A chimaeric 11 beta-hydroxylase/aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension. Nature 355: 262-265.
• Litchfield WR, Anderson BF, Weiss RJ, Lifton RP, Dluhy RG, 1998. Intracranial aneurysm and hemorrhagic stroke in glucocorticoid-remediable aldosteronism. Hypertension 31: 445-450.
• Litchtfield WR, Coolidge C, Silva P, Lifton RP, Fallo F, Williams GH, Dluhy RG, 1997. Impaired potassium-stimulated aldosterone production: a possible explanation for normokalemic glucocorticoid- remediable aldosteronism. J Clin Endocrinol Metab 82: 1507-1510.
• Litwin M, Tysarowska A, Malinowska M, Ciechanowicz A, Malunowicz E, Adler G, et al. 2002. Familial hyperaldosteronism type I: biochemical and molecular diagnosis in patient and normotensive family member. Pediatr Nephrol 17: C90.
• MacConnachie AA, Kelly KF, McNamara A, Loughlin S, Gates LJ, Inglis GC, et al. 1998. Rapid diagnosis and identification of cross-over sites in patients with glucocorticoid remediable aldosteronism. J Clin Endocrinol Metab 83: 4328-4331.
• Mulatero P, Di Cella SM, Williams TA, Milan A, Mengozzi G, Chiandussi L, et al. 2002. Glucocorticoid remediable aldosteronism: low morbidity and mortality in a four-generation Italian pedigree. J Clin Endocrinol Metab 87: 3187-3191.
• Mulatero P, Veglio F, Pilon C, Rabbia F, Zocchi C, Limone P, et al. 1998. Diagnosis of glucocorticoid remediable aldosteronism in primary aldosteronism: aldosterone response to dexamethasone and long polymerase chain reaction for chimeric gene. J Clin Endocrinol Metab 83: 2573-2575.
• Prejbisz A, Postuła M, Cybulska I, Dobrucki T, Kabat M, Peczkowska M, et al. 2003. Biochemical investigations and clinical symptomatology in diagnostics and form differentiation of primary hyperaldosteronism. Kardiol Pol 58: 17-26.
• Sutherland DJA, Ruse JL, Laidlaw JC, 1966. Hypertension, increased aldosterone secretion and low plasma renin activity relieved by dexamethasone. Can Med Assoc J 95: 1109-1119.
• Wyckoff JA, Seely EW, Hurwitz S, Anderson BF, Lifton RP, Dluhy RG, 2000. Glucocorticoid-remediable aldosteronism and pregnancy. Hypertension 35: 668-672.